IgG4-Related Disease — Written Clinical Reasoning

SAQ 1 — Integrated Diagnostic Approach to the Patient with Multi-Organ IgG4-Related Disease (20 marks, 30 minutes)

Prompt: Outline your integrated diagnostic approach to Mr Chen's presentation, addressing: (a) the unifying diagnosis and the clinicopathological reasoning; (b) the role and limits of the serum IgG4; (c) the exclusion of pancreatobiliary malignancy and Sjogren syndrome; (d) the histopathological confirmation and the 2019 ACR and EULAR classification criteria; (e) the immediate and definitive management; and (f) the common exam trap ^{[1] [3]}.

Model Answer

(a) The unifying diagnosis and the clinicopathological reasoning (3 marks): ^[1]

Mr Chen has IgG4-related disease with multi-organ involvement — the pancreatobiliary presentation (painless jaundice, a diffusely enlarged capsule-rimmed pancreas and a common bile duct stricture) is type 1 autoimmune pancreatitis with IgG4-related sclerosing cholangitis, the submandibular gland enlargement is Mikulicz syndrome, and the renal cortical lesions with the periaortic rind represent IgG4-related kidney disease with early retroperitoneal fibrosis ^[1]. The "one disease, many organs" concept is the organising principle: the simultaneous involvement of the pancreas, biliary tree, salivary glands and kidneys in an older man with atopy is pathognomonic in pattern, and the markedly elevated serum IgG4 and the characteristic imaging consolidate it. The flank discomfort and the creatinine rise from bilateral ureteric obstruction by the periaortic rind add an urgent element.

(b) The role and limits of the serum IgG4 (3 marks): ^[1]

The serum IgG4 of 3.2 g per litre (more than twice the upper limit of 1.35) is strongly supportive, because a markedly elevated IgG4 with a normal CA19-9 favours IgG4-related disease over malignancy ^[1]. Two limits must be stated. First, IgG4 is supportive, not diagnostic — it is falsely elevated in 10 to 15 per cent of pancreatobiliary cancers and cholangiocarcinoma, in primary sclerosing cholangitis, and in asthma and atopy (relevant here). Second, a normal IgG4 does not exclude the disease, because 20 to 30 per cent of biopsy-proven type 1 autoimmune pancreatitis are seronegative ^[1]. The diagnosis therefore rests on the clinicopathological pattern with histopathology as the gold standard, not on the serology.

(c) The exclusion of pancreatobiliary malignancy and Sjogren syndrome (4 marks): ^{[1] [3]}

The critical exclusion is pancreatic adenocarcinoma and cholangiocarcinoma, both of which cause a pancreatic head mass with painless jaundice and can elevate IgG4 mildly ^[1]. The features favouring IgG4-related disease over cancer are the diffusely enlarged sausage-shaped pancreas rather than a focal mass, the absence of vascular encasement, the normal CA19-9, the multi-organ involvement and the marked IgG4 elevation. Despite this, adequate tissue is required before immunosuppression — endoscopic ultrasound-guided core biopsy of the pancreas, with sufficient tissue for histology, immunostaining and, where needed, flow cytometry. A diagnostic steroid trial is unsafe when malignancy has not been excluded, because lymphoma and even cancer can transiently shrink on steroids ^[1][3].

The salivary gland enlargement is distinguished from Sjogren syndrome by the male sex, the older onset, the prominent gland enlargement rather than sicca, the negative anti-Ro and anti-La, and the elevated IgG4 ^[1]. Sjogren is female-predominant, sicca-dominant and seropositive. Lymphoma (marginal zone or MALT) must be excluded with flow cytometry on the biopsy when a gland is asymmetric or rapidly growing.

(d) The histopathological confirmation and the 2019 ACR and EULAR classification criteria (4 marks): ^[2]

The histopathology is the gold standard. The diagnostic triad is a dense lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells, storiform (cartwheel-like) fibrosis, and obliterative phlebitis (veins occluded by the infiltrate while arteries are spared), with an IgG4 to total IgG plasma cell ratio above 40 per cent ^[1][2]. The IgG4 cell count threshold is organ-specific (for example, above 30 per high-power field for pancreas), and the count is not diagnostic in isolation — it must be interpreted with the triad and the clinical context.

The 2019 ACR and EULAR classification criteria formalise the diagnosis as a three-step process: an entry criterion (characteristic organ involvement), the application of 32 exclusion criteria (any one excludes the diagnosis), and a weighted inclusion score across eight domains, with a total of 20 points or more classifying the case as IgG4-related disease ^[2]. The pathological domain carries the heaviest weight. Mr Chen meets the entry criterion, has no exclusion criterion (normal CA19-9, no cachexia, no granulomas), and would score well above 20 on the multi-organ pattern plus the marked IgG4 elevation plus the diagnostic histology.

(e) The immediate and definitive management (4 marks): ^{[3] [4]}

The immediate priority is the renal impairment from bilateral ureteric obstruction — decompress with ureteric stents or nephrostomy first, because renal recovery depends on the duration of obstruction ^[3]. In parallel, address the obstructive jaundice with endoscopic biliary drainage if the stricture is causing cholestasis or cholangitis risk. Once the obstruction is relieved and the diagnosis is histologically secure, commence prednisolone 30 to 40 mg daily for two to four weeks for the active inflammatory disease, then taper over three to six months ^[3]. Give bone protection (calcium, vitamin D, a bisphosphonate where indicated) and consider pneumocystis prophylaxis. Plan a maintenance strategy from the outset — for multi-organ disease, this is usually a planned course of rituximab (375 mg per square metre weekly for four doses, or 1 g on days 1 and 15), having first screened for hepatitis B and tuberculosis, because relapse occurs in 40 to 50 per cent and most rituximab responders relapse within a year ^[3][4].

(f) The common exam trap (2 marks): ^{[1] [3]}

The trap is to treat elevated serum IgG4 as diagnostic and to commit to a diagnostic steroid trial in a pancreatic mass without adequate tissue ^[1][3]. A radiological response to steroids can occur with lymphoma and even transiently with cancer, so tissue is mandatory before immunosuppression when malignancy is plausible. The corollary trap is to assume a normal IgG4 excludes the disease — 20 to 30 per cent of biopsy-proven type 1 autoimmune pancreatitis are seronegative, and the diagnosis is clinicopathological ^[1].